Study links two Type 2 diabetes drugs to higher risk of heart disease

          Source: Xinhua| 2018-12-23 05:11:37|Editor: yan
          Video PlayerClose

          CHICAGO, Dec. 22 (Xinhua) -- Two drugs commonly prescribed to treat Type 2 diabetes carry a high risk of cardiovascular events such as heart attack, stroke, heart failure or amputation, according to a Northwestern Medicine (NU) study.

          The two drugs, sulfonylureas and basal insulin, are commonly prescribed to patients after they have taken metformin, a widely accepted initial Type 2 diabetes treatment.

          The observational study used data from 132,737 patients with Type 2 diabetes who were starting second-line treatment.

          Some 60 percent of the patients nationwide who need a second-line drug are prescribed one of these two drugs, the study found. Yet, patients who take one of these two drugs, 36 percent more for sulfonylureas and twice as likely for basal insulin, are more likely to experience cardiovascular harm than those taking a newer class of diabetes drugs known as DPP-4 inhibitors.

          "According to our findings, we only have to prescribe basal insulin to 37 people over two years to observe one cardiovascular event, such as a heart attack, stroke, heart failure or amputation," said lead author Matthew O'Brien, assistant professor of general internal medicine and geriatrics at NU Feinberg School of Medicine and a Northwestern Medicine physician. "For sulfonylureas, that number was a bit higher, 103 people. But when you apply these numbers to 30 million Americans with diabetes, this has staggering implications for how we may be harming many patients."

          Physicians should consider prescribing newer classes of antidiabetic medications, such as GLP-1 agonists or liraglutide, SGLT-2 inhibitors or empagliflozin, and DPP-4 inhibitors or sitagliptin, more routinely after metformin, rather than sulfonylureas or basal insulin, the researchers suggest.

          These drugs, however, are more expensive than the sulfonylureas.

          This is the first study to compare how each of the six major second-line drugs impact cardiovascular outcomes in Type 2 diabetes patients taking a second diabetes medication.

          The study was published Dec. 21 in JAMA Network Open.

          TOP STORIES
          EDITOR’S CHOICE
          MOST VIEWED
          EXPLORE XINHUANET
          010020070750000000000000011105521376921981
          无码人妻一区二区三区四区av_亚洲精品911在线永久观看_精品一区二区国产在线观看_日韩不卡一区二区视频在线

                  制服丝袜国产精品主区 | 中文字幕乱码无遮挡精品视频 | 在线看片免费人成视频国产片 | 视频二区丝袜国产欧美日韩 | 亚洲中文日韩欧美v | 最新看片国产精品免费在线 |